Quality of care offered by health care retail markets for medication abortion self-management: Findings from states in Nigeria and India.

Dispensing of misoprostol and mifepristone by pharmacies and chemist shops for self-management of medication abortion (MA) fills a crucial gap in settings where abortion care by trained health professionals is not readily available. This promising service delivery pathway, endorsed by the World Health Organization (WHO), is hindered by concerns of poor-quality care. Simulated clients collected data on MA pill dispensing practices from 92 pharmacies and chemist shops in three Nigerian states and 127 pharmacies in an Indian state that we have anonymized.

Fabrication and characterisation of a flexible thermoelectric generator using PANI/graphite/bismuth telluride composites.

Unique thermoelectric properties of low-cost, widely available conducting polymers and multi-layered graphite structures have motivated the development of flexible thermoelectric generators using screen printing for low-temperature applications. Composites of polyaniline and graphite in different ratios with one weight percentage of bismuth telluride were prepared to fabricate flexible thermoelectric generators. The performance of the devices showed that the addition of graphite to polyaniline reduced the band gap energy from 2.

Learning from the lived experiences of medical women working and studying at the national hospital in Fiji: A mixed methods study.

Objective: Our study aimed to explore the experience of attaining higher education among women in medicine at the largest national hospital in Fiji, focusing on barriers and enablers to completing training, and to explore women's perception of gender-based discrimination in the world of medicine. Findings subsequently informed evidence-based recommendations on enablers and barriers at the hospital and medical university to improve experiences of women in medicine.

Methods: We conducted a mixed-method study, emphasising the phenomenological qualitative component.

Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A.

Background: Severe hemophilia A is managed with factor VIII replacement or hemostatic products that stop or prevent bleeding. Data on gene therapy with hematopoietic stem-cell (HSC)-based expression of factor VIII for the treatment of severe hemophilia A are lacking.

Methods: We conducted a single-center study involving five participants 22 to 41 years of age with severe hemophilia A without factor VIII inhibitors.